The anxiolytic-like effect of ginkgo biloba extract and the constituents assessed by an improved plus-maze test in mice

Japanese Pharmacology and Therapeutics

Volumn 30, Issue 11, 2002, Pages 955-962

  Kuribara, Hisashi ^a   Maruyama, Yuji ^a   Yoshihama, Tatsumi ^a  

^a NONE

Author keywords

Ambulatory activity; Anxiolytic like effect; Elevated plus maze; Ginkgo biloba extract; Ginkgolide A; Mice

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR; BILOBALIDE; DIAZEPAM; FLUMAZENIL; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C;

ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MAZE TEST; MOTOR ACTIVITY; MOUSE; NONHUMAN;

EID: 0036947723     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Meltzer HY, editor. Psychopharmacology. The Third Generation of Progress. New York.: Raven Press; 1987.
2. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Alternat Therap 2001; 7: 70-90.
3. Bauer U. 6-month double-blind randomized clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim Forsch 1984; 34: 716-21.
4. Rudofsky VG. The effect of Ginkgo biloba extract in cases of arterial occlusive disease. A randomized placebo controlled double-blind cross-over study. Fortschr Med 1987; 105: 397-400.
5. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136-9.
6. Schneider B. Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled clinical studies. Arzneim Forsch 1992; 42: 428-36.
7. Corrigan D. Fossil medicine-Ginkgo biloba. Eur J Herb Med 1995; 1: 16-8.
8. Editorial Office of AJNM. Intermittent claudication: Trental vs. Ginkgo biloba extract. Am J Natl Med 1995; 2: 10-3.
9. Wong AH, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55: 1033-44.
10. Beaubrun G, Gray GE. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 2000; 51: 1130-4.
11. Topic B, Hasenohrl RU, Hacker R, Huston JP. Enhanced conditioned inhibitory avoidance by a combined extract of Zingiber officinale and Ginkgo biloba. Phytother Res 2002; 16: 312-5.
12. Topic B, Tani E, Tsiakitzis K, Kourounakis PN, Dere E, Hasenohrl RU, et al. Enhanced maze performance and reduced oxidative stress by combined extracts of Zingiber officinale and Ginkgo biloba in the aged rat. Neurobiol Aging 2002; 23: 135-43.
13. Hasenohrl RU, Nichau CH, Frisch CH, De Souza Silva MA, Huston JP, Mattern CM, et al. Anxiolytic-like effect of combined extracts of Zingiber officinale and Ginkgo biloba in the elevated plus-maze. Pharmacol Biochem Behav 1996; 53: 271-5.
14. Hasenohrl RU, Topic B, Frisch C, Hacker R, Mattern CM, Huston JP. Dissociation between anxiolytic and hypomnestic effects for combined extracts of Zingiber officinale and Ginkgo biloba, as opposed to diazepam. Pharmacol Biochem Behav 1998; 59: 527-35.
15. Satyan KS, Jaiswal AK, Ghosal S, Bhattacharya SK. Anxiolytic activity of ginkgolic acid conjugates of Indian Ginkgo biloba. Psychopharmacology 1998; 136: 148-52.
16. Porsalt RD, Martin P, Lenegre A, Fromage S, Drieu K. Effects of an extract of Ginkgo biloba (EGb 761) on "learned helplessness" and other models of stress in rodents. Pharmacol Biochem Behav 1990; 36: 963-71.
17. Chermat R, Brochet D, De Feudis FV, Drieu K. Interations of Ginkgo biloba extract (EGb 761), diazepam and ethyl beta-3-carboxylate on social behavior in the rat. Pharmacol Biochem Behav 1997; 56: 333-9.
18. Brochet D, Chermat R, De Feudis FV, Drieu K. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. Gen Pharmacol 1999; 33: 249-56.
19. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-67.
20. Biber A, Koch E. Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med 1999; 65: 192-3.
21. Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract EGb 761 and isolated ginkgolides. Endocrinology 1996; 137: 5708-18.
22. Amri H, Drieu K, Papadopoulos V. Ex vivo regulation of adrenal cortical cell steroid and protein synthesis, in response to adrenocorticotropic hormone stimulatory, by the Ginkgo biloba extract EGb 761 and isolated ginkgolide B. Endocrinology 1997; 138: 5415-26.
23. De Deyn PP, Macdonald RL. CGS 9896 and ZK 91296, but not CGS 8216 and Ro 15-1788, are pure benzodiazepine receptor antagonists on mouse neurons in culture. J Pharmacol Exp Ther 1987; 242: 48-55.
24. White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 1996; 58: 1315-21.
25. Maruyama Y, Kuribara H, Morita M, Yuzurihara M, Weintraub ST. Identification of magnolol and honokiol as anxiolytic agents in extracts of Saiboku-to, an oriental herbal medicine. J Natl Prod 1998; 61: 135-8.
26. Kuribara H, Kishi E, Hattori N, Yuzurihara M, Maruyama Y. Application of the elevated plus-maze test in mice for evaluation of the content of honokiol in water extracts of magnolia. Phytother Res 1999; 13: 593-6.
27. Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. J Pharm Pharmacol 2000; 52: 1425-9.